Tyvaso (6 Microgram, Aerosol For Inhalation) (Treprostinil Sodium)


Indications and Reactions:

Role Indications Reactions
Primary
Pulmonary Arterial Hypertension 43.9%
Cor Pulmonale Chronic 22.0%
Primary Pulmonary Hypertension 12.7%
Chronic Pulmonary Heart Disease 7.5%
Pulmonary Hypertension 4.0%
Product Used For Unknown Indication 3.5%
Pulmonary Hypertension Secondary 1.2%
Pulmonary Arterial Hypertension 0.6%
Pulmonary Hypertension Secondary 0.6%
Associated With Pulmonary Arterial Hypertension 0.6%
Idiopathic Pulmonary Arterial Hypertension 0.6%
Inhalation 0.6%
Portopulmonary Hypertension 0.6%
Pulmonary Fibrosis 0.6%
Pulmonary Hypertension Primary 0.6%
Systemic Sclerosis 0.6%
Death 65.4%
Dyspnoea 3.1%
Bronchitis 2.4%
Hypotension 2.4%
Pneumonia 2.4%
Pulmonary Arterial Hypertension 2.4%
Syncope 2.4%
Gastrointestinal Haemorrhage 1.6%
Headache 1.6%
Loss Of Consciousness 1.6%
Lung Disorder 1.6%
Oxygen Saturation Decreased 1.6%
Pulmonary Hypertension 1.6%
Pulmonary Oedema 1.6%
Respiratory Failure 1.6%
Sepsis 1.6%
Sudden Death 1.6%
Vomiting 1.6%
Weight Decreased 1.6%
Bronchospasm 0.8%
Secondary
Pulmonary Arterial Hypertension 66.7%
Product Used For Unknown Indication 16.7%
Pulmonary Hypertension 16.7%
Infusion Site Pain 33.3%
Tachycardia 33.3%
Tricuspid Valve Incompetence 33.3%

Drug Data